Macrocyclic Peptides Inhibit ROR1 via Specific Binding
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies for cancer, particularly those targeting ROR1, lack effective and innovative solutions for inhibiting ROR1 activity, which is critical for cancer progression and is expressed in various hematological and solid tumors.
Innovation Solution
Development of novel anti-ROR1 macrocyclic peptides and their conjugates that specifically bind to the extracellular domain of human ROR1, offering a new approach to inhibit ROR1 activity and treat related diseases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional antibody therapies or small molecule inhibitors are used to target ROR1, then ROR1 inhibition can be achieved, but the therapies lack effectiveness and innovation for treating various ROR1-positive cancers
Solution Approach 1:
The patent employs macrocyclic peptide structures with specific cyclic constraints and side chain modifications to alter the binding parameters and affinity for ROR1, achieving improved inhibition effectiveness compared to conventional linear peptides or antibodies
Solution Approach 2:
The invention creates composite therapeutic agents by conjugating macrocyclic peptides with cytotoxic payloads, radioactive isotopes, or fluorescent markers, enabling multi-functional therapy that combines ROR1 inhibition with targeted delivery and imaging capabilities
2Ease of operation
If existing ROR1-targeted therapies are developed, then some ROR1 inhibition activity can be achieved, but they do not provide sufficient specificity and efficacy across multiple cancer types
Solution Approach 1:
The patent introduces specific local modifications at key binding positions within the macrocyclic peptide structure, including constrained cyclic regions and tailored side chains, to enhance local interaction quality and specificity with ROR1 binding sites
Solution Approach 2:
The macrocyclic peptide platform is designed with universal ROR1 binding capability that can be applied across multiple cancer types, while allowing for modular conjugation of different therapeutic payloads to address diverse clinical needs
Data Source
AI summary
There are disclosed novel anti-ROR1 macrocyclic peptides and their conjugates with general structure of formula (I), which can be used as ROR1 inhibitors.